Lerisetron (code name F-0930-RS) is a drug which acts as an antagonist at the 5-HT3 receptor.[1] It is a potent antiemetic[2][3] and was in clinical trials for the treatment of nausea associated with cancer chemotherapy.[4]
Clinical data | |
---|---|
Other names | F-0930-RS |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H20N4 |
Molar mass | 292.386 g·mol−1 |
| |
(what is this?) (verify) |
See also
editReferences
edit- ^ Orjales A, Mosquera R, Labeaga L, Rodes R (February 1997). "New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation". Journal of Medicinal Chemistry. 40 (4): 586–93. doi:10.1021/jm960442e. PMID 9046349.
- ^ Gomez-de-Segura IA, Grande AG, De Miguel E (1998). "Antiemetic effects of Lerisetron in radiation-induced emesis in the dog". Acta Oncologica. 37 (7–8): 759–63. doi:10.1080/028418698430160. PMID 10050999.
- ^ Cooper M, Sologuren A, Valiente R, Smith J (2002). "Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers". Arzneimittel-Forschung. 52 (9): 689–94. doi:10.1055/s-0031-1299952. PMID 12404884. S2CID 24423582.
- ^ Huckle R (July 2003). "Lerisetron. FAES". Current Opinion in Investigational Drugs. 4 (7): 874–7. PMID 14619411.